Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 92 Breast Neoplasms 69 Prostatic Neoplasms 33 Triple Negative Breast Neoplasms 32 Neoplasms 26 Fallopian Tube Neoplasms 25 Neoplasm Metastasis 21 Endometrial Neoplasms 19 Pancreatic Neoplasms 18 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 12 Carcinoma, Non-Small-Cell Lung 10 Stomach Neoplasms 9 Sarcoma 9 Recurrence 9 Lung Neoplasms 9 Fanconi Anemia, Complementation Group D1 9 Squamous Cell Carcinoma of Head and Neck 8 Glioma 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Glioblastoma 7 Colorectal Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 5 Lymphoma, Non-Hodgkin 5 Cholangiocarcinoma 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Solid Tumors 4 Osteosarcoma 4

Interventions

olaparib 1 niraparib 1 fluzoparib 1 Vernalization 1 Standard of Care 1 Poly(ADP-ribose) Polymerase Inhibitors 1 Irinotecan 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Kenny-Caffey syndrome, Type 1 × olaparib × Clear all

NCT05044091 2021-09-14

HOPEI

Jiangsu Cancer Institute & Hospital

Kenny-Caffey syndrome, Type 1, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡